BioMarin snags cash as Sarepta skips Duchenne patent battle
Sarepta Therapeutics Inc. agreed to pay $35 million plus royalties and potential milestones to BioMarin Pharmaceutical Inc. to resolve a dispute over patents on its Duchenne muscular dystrophy drug.
Sarepta (NASDAQ: SRPT) said Tuesday it had reached an agreement to license the intellectual property of San Rafael-based BioMarin (NASDAQ: BMRN), which had challenged key patents covering Sarepta’s approved Duchenne drug, Exondys 51 as well as other so-called “exon-skipping” treatments.
Tre nding:…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Max Stendahl Source Type: news